American/Hungerford is a part of Masco Contractor Services and offers various forms of insulation installations such as popular batt, gutter installation and gutter protection services and blow applications. The company serves both homebuilders and homeowners. Expansion in the New York area will further broaden the company�� client base.
Recently, other Masco Contractor Services units, Williams Insulation and Red Lion Insulation also announced their expansion plans. Williams Insulation plans to expand into Lake Charles, La. while Red Lion Insulation plans to expand into Farmingdale, N.J. Both the companies offer various forms of insulation installations such as fiberglass batt, blown fiberglass, spray foam and cellulose.
Masco manufactures, sells and installs home improvement and building products.It is scheduled to report its second quarter 2013 earnings results on Jul 30, 2013. The Zacks Consensus Estimate for the quarter stands at 19 cents per share. The Zacks Consensus Estimate for 2013 is 69 cents while that for fiscal 2014 is $1.02 per share.
Top 5 Rising Companies To Own For 2015: Fenner PLC (FENR)
Fenner PLC is a manufacturer and distributor of reinforced polymer products. It operates in two segments: engineered conveyor solutions, which is engaged in the manufacture of rubber, polyvinyl chloride and steel cord conveyor belts, ply, solid woven and steel cord conveyor belting for mining, power generation and industrial applications and advanced engineered products, which is engaged in the manufacture of precision polymer products; problem-solving power transmission and motion transfer components; silicone and complex hoses for heavy duty trucks, buses and off-road vehicles; seals and sealing solutions for the fluid power and oil and gas industries; technical textiles for medical and industrial applications and silicone based products for medical applications; rollers for digital image processing and medical diagnostics, and fluropolymer components for fluid and gas handling. Advisors' Opinion:- [By Inyoung Hwang]
Fenner Plc (FENR) rallied 5.2 percent to 407.4 pence, its highest price since March 20. UBS AG started coverage of the conveyor-belt maker with a buy rating, saying shares are cheap. The bank predicted the stock will climb to 460 pence in the next 12 months.
5 Best Building Product Stocks To Buy Right Now: Powershares Dynamic Pharmaceuticals Portfolio (PJP)
PowerShares Dynamic Pharmaceuticals Portfolio seeks investment results that correspond generally to the price and yield, before fees and expenses, of the Dynamic Pharmaceuticals Intellidex Index (the Pharmaceuticals Intellidex). The Fund will normally invest at least 80% of its total assets in common stocks of pharmaceutical companies. The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Pharmaceuticals Intellidex. PowerShares Capital Management LLC (the Adviser) is the investment adviser for the Funds.
The Pharmaceuticals Intellidex comprises stocks of 30 United States-based pharmaceutical companies. These are companies that are principally engaged in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. These companies may include, pharmaceutical companies and other companies involved in the research, development, manufacture, sale or distribution of drugs, including companies that facilitate the testing or regulatory approval of drugs.
Advisors' Opinion:- [By Jim Lowell]
Meanwhile, the PowerShares Dynamic Pharmaceuticals (PJP) has grabbed the top spot among sector ETFs.
The fund seeks investment results that correspond to the price and yield performance of the Dynamic Pharmaceuticals Intellidex Index, which is made up of 30 US companies involved in the research, development, production, sale, or distribution of pharmaceuticals and drugs.
- [By Gary Gordon]
On behalf of most of my clients in 2013, I chose to overweight tech and health care. However, I did so with areas that are traditionally less volatile. I continue to own Powershares Pharmaceuticals (PJP) and/or SPDR Select Healthcare (XLV). I’ve been a proponent of “old tech” with the attractive prices and dividends; First Trust NASDAQ Tech Dividend (TDIV) fits the bill. Additionally, I have remained faithful to iShares Small Cap Value (IJS) for small-cap exposure, rather than hop on the IWO express.
5 Best Building Product Stocks To Buy Right Now: Biodel Inc (BIOD)
Biodel Inc. (Biodel), incorporated on December 3, 2003, is a development-stage speciality biopharmaceutical company focused on the development and commercialization of treatments for diabetes. The Company develops its product candidates by applying its formulation technologies to existing drugs. Its advanced program involves developing formulations of injectable recombinant human insulin (RHI). In addition to its ultra-rapid-acting insulin formulations, the Company has developed prototype formulations of a liquid glucagon, a basal insulin and a glucose responsive insulin, in each case for use by patients with diabetes. RHI-based formulation known as Linjeta was the subject of a New Drug Application (NDA).
The Company has two pivotal Phase III clinical trials with its preferred commercial formulation of Linjeta prior to re-submitting the NDA. In August 2011, it completed patient visits and analyzed top-line data from the first Phase 1 clinical trial of two RHI-based formulations. The trial was a single-center, randomized, double-blind, three-period crossover trial in 18 subjects with Type 1 diabetes. The purpose of the trial was to evaluate the pharmacokinetic and pharmacodynamic characteristics and injection site toleration of BIOD-105 and BIOD-107, as compared to the insulin analog marketed as Humalog. The Company conducted Phase I, Phase II and Phase III clinical trials comparing the performance of its Linjeta formulation of RHI to either Humulin, which is a branded formulation of RHI or Humalog. Its pivotal Phase III clinical trials were open-label, parallel group, randomized trials conducted at centers in the United States, Germany and India.
The Company competes with Eli Lilly, Novo Nordisk, Sanofi-Aventis, Halozyme Therapeutics, Inc. and MannKind Corporation.
Advisors' Opinion:- [By Roberto Pedone]
One under-$10 specialty biopharmaceutical player that's starting to trend within range of triggering a big breakout trade is Biodel (BIOD), which is focused on the development and commercialization of innovative treatments for diabetes. This stock has been hit hard by the bears over the last three months, with shares down by 24%.
If you take a look at the chart for Biodel, you'll notice that this stock is ripping higher here right off its 50-day moving average of $2.32 a share with strong upside volume. Volume on Thursday has so far registered over 750,000 shares, which is well above its three-month average action of 445,084 shares. This move is quickly pushing shares of BIOD within range of triggering a big breakout trade.
Traders should now look for long-biased trades in BIOD if it manages to break out above some near-term overhead resistance levels at $2.52 to $2.60 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 445,084 shares. If that breakout triggers soon, then BIOD will set up to re-test or possibly take out its next major overhead resistance levels $3 to its 200-day moving average of $3.39 a share. Any high-volume move above $3.39 will then give BIOD a chance to tag $4 a share.
Traders can look to buy BIOD off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support at $2.10 a share. One can also buy BIOD off strength once it starts to clear those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
- [By Monica Gerson]
Biodel (NASDAQ: BIOD) is expected to post a Q1 loss at $0.24 per share.
First Majestic Silver (NYSE: AG) is estimated to post its Q1 earnings at $0.10 per share on revenue of $63.35 million.
5 Best Building Product Stocks To Buy Right Now: BGC Partners Inc.(BGCP)
BGC Partners, Inc. operates as a financial intermediary to the financial markets specializing in the brokering of various financial products. It provides electronic marketplaces, including government bond markets, spot foreign exchange, foreign exchange options, corporate bonds, and credit default swaps in various financial markets through its eSpeed- and BGC Trader- branded trading platform which can be accessed through its high speed data network, over the Internet, or third party communication networks. The company?s brokerage services include trade execution, broker-dealer services, clearing, processing, information, and other back office services, as well as cover various products, including fixed income securities, interest rate swaps, foreign exchange, equities, equity derivatives, credit derivatives, commodities, futures, and structured products. It also provides financial technology solutions, market data, and analytics related to financial instruments and markets . In addition, the company offers customized screen-based market solutions, which enables its clients to develop a marketplace, trade with their customers, issue debt, trade odd lots, access program trading interfaces, and access its network and intellectual property. Further, it licenses intellectual property portfolio and software solutions to various financial markets participants; and provides software development, software maintenance, customer support, infrastructure, and internal technology services to support electronic trading platforms. The company serves banks, broker-dealers, investment banks, trading firms, hedge funds, governments, investment firms, professional trading firms, futures commission merchants, and other professional market participants and financial institutions in the United States, the United Kingdom, France, Asia, Europe, Africa, the Middle East, and other Americas. The company was founded in 1999 and is based in New York, New York.
Advisors' Opinion:- [By Eric Volkman]
BGC Partners (NASDAQ: BGCP ) is waxing optimistic about its current quarter. The company updated its previously issued guidance, indicating that its nearly complete Q2 will come in at the higher end of the range for revenues and EPS. The former was for distributable earnings revenue of $435 million-$465 million, while the latter anticipated pre-tax distributable earnings of $42 million-$53 million.
- [By Selena Maranjian]
Finally, Tudor Investment's biggest closed positions included Apple�and the iShares MSCI Emerging Market Index Fund ETF. Other closed positions of interest include Frontier Communications (NASDAQ: FTR ) and BGC Partners (NASDAQ: BGCP ) . Frontier, recently yielding more than 9%, is a rural telecom specialist. It's weighed down with considerable debt, and is shifting its business focus, favoring business customers more. It's been posting declining revenue lately, though, and its credit rating took a hit in recent months, also. Some worry that its acquisition of landline business from Verizon�may not be as lucrative as expected, and fear a dividend cut.
- [By Brian Womack]
��t�� a defensive strategy because R&D costs are going up and the number of customers is going down,��said Amir Anvarzadeh, a manager of Japanese equity sales at BGC Partners Inc. (BGCP) in Singapore. ��his tells you there�� a problem in the industry.��
No comments:
Post a Comment